ms international federation

Report and financial statements for the year ended 31 December 2018

Multiple Sclerosis International Federation

(A company limited by guarantee)

Company registration number:	05088553
Charity registration number:	1105321
Registered address:	Skyline House, 200 Union Street, London SE1 0LX

Contents

Introduction 3

Who we are and what we do 4

  How we measure and assess success 4

  Grant making policy 5

Governance for a global movement 7

  Public benefit 9

Trustees report 10

  MSIF's progress against 2018 priorities 10

  Looking ahead, 2019 priorities 20

Statement of trustees' responsibilities 22

Independent auditor's report to the members of Multiple Sclerosis International Federation 23

Statement of financial activities 26

Balance sheet as at 31 December 2018 27

Cash flow statement for the year ended 31 December 2018 28

Prior year Statement of financial activities 29

Notes to the financial statements 30

Introduction

During 2018, the MS International Federation and its members – the global MSIF Movement – have advanced many key objectives in our strategy 'Together we're Stronger than MS'. This report provides an overview of the exciting progress made by the Movement.

We have together improved scientific understanding of MS and accelerated new treatments, strengthened our global movement and the many collaborations within it, ensured that people affected by MS have the information they need to make confident and informed decisions, and advocated for positive changes in attitudes, policies and practices.

At the heart of our strategy is a unified vision. This vision guides not just the MSIF secretariat, but rather the entire MS Movement which works together to pursue its aims. Through this approach of collaboration and active engagement, we ensure that the expertise and resources of MSIF's members are put to global use.

This approach has led to great progress in our newest aim of improving access to effective treatments and healthcare. With the enthusiastic engagement from staff across key member organisations as well as from several crucial medical and research practitioners, we have made a proposal to the World Health Organization, which – if accepted – will be an important step towards such improved access to treatment.

It is said that MS has a thousand faces. Our movement hosts many countries, many cultures and many different realities of what it means to live with MS. In this report, you will see the many diverse parts of the Movement that have contributed, as well as the many areas where we have an impact on the lives of people affected by MS around the world.

Weyman Johnson

Chairman

Who we are and what we do

The Strategy for 2017-2021

'Together we're stronger than MS' is the strategy for the whole global MSIF movement.

The focus of this strategy is to mobilise the entire MSIF movement; organisations, people affected by MS, volunteers and staff, to achieve our common mission: To bring the world together to improve the quality of life of everybody affected by MS and to end MS forever.

We are building a stronger, broader, global movement made up of effective MS organisations, engaged individuals and strategic international collaborations. Together we tackle challenges for people affected by MS in countries rich and poor.

Our aims, objectives and activities

Our five aims show the impact we aim to achieve as a movement over the next 10 to 15 years. These aims are connected and support each other. In order to work towards these aims, we have identified a number of objectives and actions for the five year strategic period. See more: www.msif.org/about-ms/our-strategy/. The table below outlines those we set out to achieve in 2018.

The long term Aims in the 2017-2021 Strategy	2018 objectives and actions towards these aims
Better scientific understanding leading to new ways to treat, prevent and stop MS.	• Advance systems for enabling data sharing • Develop a way to measure the impact of research
Improved access to effective treatments and Health care.	• Develop an approach to address barriers to accessing treatments
Access to accurate and trustworthy information and resources to make informed decisions to live well with MS.	• Repurpose and translate materials for adaption and use around the world • Build networks of membership staff and volunteers in communications, care and services.
Positive changes in policies and practices, attitudes and behaviours that are obstacles to living well with MS	• Develop advocacy tools for national, local and individual action
A stronger, broader MSIF movement made up of effective MS organisations, engaged individuals and strategic international collaborations	• Strengthen MS organisations in countries with challenging socio-economic conditions • Enhance the effectiveness of member organisations and MSIF • Ensure effective and inclusive international collaborations • Strengthen communication and networking across the MSIF movement

Contribution of volunteers

One volunteer supports the MSIF Secretariat in the organisation of its biannual international networking meetings. Our trustees are unpaid volunteers.

How we measure and assess success

MSIF sets annual milestones and longer term objectives for each project and for the strategy and organisation as a whole, the latter is available to the public in MSIF's 2017-2021 Strategy on www.msif.org/about-us/reports-and-resources

We regularly monitor and evaluate projects against these indicators in order to learn and continuously improve the effectiveness of our work, ensure accountability and good governance. Annual reports are prepared for major funders, with six-monthly updates provided to the board and all members through a Strategy Progress Report. Our annual trustee report and accounts are published on our website.

Methods we use to assess and measure success include:

- Surveys of our membership and/or the global MS community e.g. World MS Day evaluation survey, survey of our research grant recipients;
- Number of subscribers to our e-newsletters;
- Number of new MS organisations fulfilling MSIF membership criteria;
- Number of downloads of our information resources, advocacy publications and toolkits;
- Number of MS organisations and individuals taking part in our events e.g. World MS Day;
- Comparison of organisational self-assessments made during capacity building projects;
- Qualitative feedback gathered via focus group discussions and semi-structured interviews;
- Reports by external consultants on the results and effectiveness of MSIF's projects;
- Logs of any complaints received and our response to them;
- Evaluation forms from training, conference and meeting attendees.

Ultimately MSIF's purpose is to benefit people with and affected by MS around the world, both through our member organisations and network but also directly, especially where no such MS organisations exist. To help assess our success in our People with MS Advisory Committee provides advice to the board on any issues in relation to the needs of people with and affected by MS. A number of our project work groups, have members who have or are affected by MS, as does our Board of Trustees. We also consult with a wider network of people with and affected by MS.

During 2018, we received no complaints. Selections of feedback from evaluation forms etc. have been incorporated, into the trustee's report of progress against 2018 priorities.

Grant making policy

Capacity building grants

Capacity building grants aim to support emerging organisations, or representatives of those organisations, in countries with economic challenges and/or a less well-developed civil society sector and are awarded on the judgement of MSIF staff. These grants are either given to registered organisations, emerging MS support structures or to service providers/consultants. In exceptional cases grants are paid to intermediary non-governmental organisations or individuals to help them undertake capacity building work to help create a local MS support structure.

The grants are given for time-limited project work (e.g. production of materials, training opportunities or awareness-raising activities) or for travel to MSIF or other meetings and training events.

Travel grants to MSIF meetings normally require that grantees pay part of the costs themselves or find match- funding.

Project or activity grants are awarded through a thorough and (where appropriate) competitive process, through public tendering and/or calls for applications.
Such criteria may involve both organisational and country factors, such as:

- Due diligence in relation to the organisations involved (including: audited accounts; official registration documents; satisfactory capacity and processes to implement the grant)
- Organisation type (patient-led/health professional-led)
- Organisations' responsiveness and readiness
- MS prevalence rate

- Accessibility to treatment by people with MS
- Travel risk
- World Bank country classifications (e.g. per capita income and poverty rates).

These grants are decided by a panel of staff members of the MSIF Secretariat and formalised in grant agreements. They are normally provided in instalments dependent on reporting on progress towards objectives and expenditure.

Some other grants, for example those relating to World MS Day, are used to support a wider range of organisations and members.

Research grants and awards

Research grants aim to encourage or facilitate international collaboration in medical or socio economic research into MS and through this the search for understanding the cause, for better treatment and ultimately to end MS.

Grants may be provided to institutions, groups of researchers or individual researchers. The grants to individuals have a strong emphasis on researchers from emerging countries and also aim to reinforce research and clinical capacity in such countries, as well as the development of MS organisations.

Grants may be given in the form of:

- Fellowships or travel grants for researchers to spend time gaining experience in another country (McDonald Fellowship and Du Pré grant)
- Awards in recognition of life time achievements or outstanding research contributions (Charcot Award and Young Investigator Award)
- Ad-hoc contributions to certain international research collaborations

Calls for proposals are normally publicly distributed within the research community and publicised on MSIF's website and mostly judged on a competitive basis by panels of members from MSIF's International Medical and Scientific Board (IMSB).

Ad hoc grants may be made on the basis of established priorities in MSIF's strategy and decided by the CEO, seeking advice from the chair of the IMSB and/or its Executive Committee or other qualified researchers.

Criteria used to decide on grants may include:

- Scientific merit of the proposals
- Relevance to MSIF's strategic priorities
- Income category of the researcher's country ('emerging countries': with a low, lower middle or upper middle income as defined by the World Bank)
- Extent of international and collaborative involvement

Where grants are awarded for the duration of more than one year they are paid in instalments, subject to reporting on progress and expenditure.

Governance for a global movement

Governing document and Board of Trustees

Multiple Sclerosis International Federation is a charity established under a Memorandum and Articles of Association and incorporated as a company limited by guarantee and not having a share capital on 30 March 2004. The Federation was registered with the Charity Commission on 5 August 2004.

For the purpose of the Companies Act 2006, the Board of trustees is regarded as the Board of Directors of the company. The trustees of the company throughout the period are as follows:

Methods for recruiting, appointing, training trustees

The Council, MSIF's supreme governing body, elects a Nominating Committee. The Nominating Committee reviews skills required for the Board and invites MSIF member organisations and relevant others to nominate candidates. It reviews submissions, interviews candidates when necessary and meets to discuss and finalise a slate of candidates to fill all Board positions. The Committee distributes supporting papers to Council members and submits them with the slate for discussion and election. Under the Articles of Association the members of the Board of Trustees are elected at the biennial Council Meeting. The Board shall consist of no less than three members. Guidance is in place for rotation of Board members.

New trustees receive written induction information upon appointment, attend an induction within the first six months of appointment and are allocated a mentor from among the longer-serving trustees.

Charity Code of Governance

As a global organisation based in the United Kingdom, MSIF follows and benefits from the regulatory framework and standards in the highly developed Charity sector in the UK adding elements that reflect its international character.

In 2018 the Board adopted the key principles of the Charity Code of Governance, which is considered an important standard for governance in the UK charity sector. The Code has been used as a framework for review in our committees and board. This has highlighted our good practice and identified a few areas in need of improvement.

There is a recommendation within the code for board size of between 5 – 12 trustees. Our board currently numbers 24. We have members and organisations we work with in more than 90 countries and continue to grow our reach, including in areas where support for people affected by with MS is patchy. It is our opinion, that having this larger board gives us greater diversity and is more representative of the communities and countries we operate in. Diversity and inclusion provide more breadth of opinion and experience in the discussions and decision making that take place across the organisation. The Board of trustees values people's differences and is fully committed to encouraging diversity. This cycle we have taken steps to recruit more people with MS and younger people as Trustees. We will strive to have at least 25% of seats on the board filled by people with MS by 2021. It is important that the voices of people with MS are heard in the Board, and we want to send a strong message to the outside world that all operations of the Federation support this.

We continue to monitor the effectiveness of our board through an annual evaluation of its own skills and performance and of individual trustees, and that of its committees internally and externally. In April 2019 our board will be working with an external facilitator as part of this process.

Risks and risk-management

The trustees have given consideration to the major risks to which the charity is exposed and satisfied themselves that systems or procedures are established in order to manage those risks.

Every six months the trustees review the major governing, operational and financial risks which the Federation faces and adjust mechanisms to lessen these risks when judged necessary and consider how to manage them when they might occur. The risk register gets updated accordingly.

Some of the risks are more temporary, such as the present risk that the reaction of MSIF's membership organisations to the call for financial commitments does not meet the movement's strategic ambition

Other risks are more permanent and include the risk of individual health care companies' changes in strategy and reducing or stopping grants to MS patient organisations.

Equally the risk of sudden political instability or of security or disaster in a country where we operate, including the risk to staff is always present. Control procedure include following foreign office travel advice and use of insurance company security briefings, as well as adequate travel and event insurance.

Another permanent risk is that of adverse publicity, due to a failing for example in governance or fundraising practice, leading to reduced trust and confidence, for example amongst beneficiaries and funders.

Management and structure

The structure of the organisation consists of a Council, made up of representatives from its member organisations, that elects the Board of Trustees. In 2018, the trustees held two meetings, the first in Amsterdam and Zandvoort in the Netherlands, facilitated by our Dutch member, Stichting MS Research, in April; the second meeting held in Rome, Italy, facilitated by our Italian member, Associazione Italiana Sclerosi Multipla

Trustees are responsible for the overall strategic direction of the charity while decisions on tactical means to achieve these objectives are taken by the Chief Executive in conjunction with staff and with input from people affected by MS, member organisations and other stakeholders throughout the world.

Additionally, operational working groups often made up from staff and or volunteers from Member

Organisations, take on responsibilities for specific projects, either reporting to the CEO or directly to the board of trustees depending on the nature of each project.

Pay and remuneration

Pay and remuneration levels of the CEO are set by the Chair of the Board of Trustees at the time of recruitment in consultation with other key board members, taking into account the skills set and experience required, the remuneration of CEOs of comparable organisations in the UK and abroad and what the charity can afford. Pay and remuneration levels of other key management personnel are set by the CEO according to the same principles.

Annual increases in pay and remuneration follow the same policies, including inflation and performance increments generally set at the same percentages, as for all staff. Ratio between highest and lowest paid staff in the organisation is a maximum of 4.

Chief Executive	Peer Baneke
Deputy CEO	Ceri Angood Napier (with Nick Rijke as Interim Deputy CEO during Ceri's absence for the second half of the year)

Bankers

Coutts & Co.
440 Strand,
London WC2R 0QS

CCLA Investment Management Ltd, COIF
Charity Funds, Senator House, 85 Queen
Victoria Street London EC4V 4ET

Auditors

Kingston Smith,
Devonshire House
60 Goswell Road
London EC1M 7AD

Solicitors

Collyer-Bristow LLP,
4 Bedford Row,
London WC1R 4DF

Public benefit

The trustees confirm that they have complied with the duty in section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit. In line with this we are committed to providing high quality information and services to the global MS community. As well as offering services and information for our network of MS organisations, the vast majority of our materials containing information for people with and affected by MS, clinicians, and advocates can be accessed by the public via our website www.msif.org.

In agreeing our activities for each year we have regard to the legal responsibilities outlined in the Charity Commission's general guidance on public benefit. The trustees always ensure that the programmes are in line with our charitable objects as set out in MSIF's governing document the Articles of Association.

The benefits of our activities for individuals are available worldwide and have most relevance in those areas where the incidence of MS is highest. They are not dependent on membership of MSIF or of one of the national MS organisations. They are directed in the main to people with MS, their caregivers, their families and others affected by it.

Trustees report

The trustees present their report and financial statements for the period ended 31 December 2018. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" issued 2015 in preparing the annual report and financial statements of the charity.

MSIF's progress against 2018 priorities

In MSIF's Report and Financial statements for the year ending 2017 we set out objectives and actions to contribute to the aims outlined in our 2017-2021 Strategy. Here we restate those objectives and report on the progress we have made in the year towards them, the difference we have made and what we have learnt.

To contribute to our aim of: Better scientific understanding leading to new ways to treat, prevent and stop MS.

We set objectives for 2018 to:

- Advance systems for enabling data sharing
- Develop a way to measure the impact of research

Data sharing

We have established a working group for international Patient Reported Outcomes (iPRO), with the Italian MS Society (AISM) as lead agency together with a team of staff from the US, UK, Australia and Germany, as well as a representative of our sister organisation, The European MS Platform (EMSP). Outcomes of clinical trials and data collected in registries often focus on outcome measures reported by healthcare professionals. This iPRO initiative explores which outcomes reported by patients are the most meaningful, effective and useful for people with MS and regulatory bodies. It will investigate the feasibility of global collaborations for registries or databases in relation to PROs. The work builds on and aligns with existing PRO initiatives (e.g. iConquer MS, PROMOPROMS etc.) If required, the iPRO work will establish a funding mechanism to support research to further validate or create new PRO measures. The mission of the project is to ensure that relevant PROs will be taken up by clinical practice and regulatory/HTA agencies – which we hope will contribute to research on more treatments that make a real difference in the quality of life of people with MS. During 2018 we launched a landscape analysis of any relevant studies already performed on this topic. In the second half of the year other organisations also took initiatives in the same area of work and we used the opportunity to explore if further collaboration with them might lead to greater progress in this field. We hope to conclude this exploration early in 2019, with appropriate adjustments to the project goals and implementation.

Measuring of the impact of research

Several MS organisations are struggling with the challenges of measuring the impact of the research they fund. The impact of different research programs needs to be measured to guide research strategy (both at national and international level) and to inform the public of the benefit of their investment. The MSIF Research Staff Network has identified this as a priority. We await results from the UK MS Society's pilot study on research impact and the Italian MS Society's research project on impact in order to share this.

In addition to progress in the above two areas we have also made progress towards the following objectives in our 2017-2021 strategy:

Make substantial progress in the search for treatments

Collaborate in the Progressive MS Alliance to remove barriers to the development of treatments

We have continued to play an active role in the governance and work-teams (scientific, fundraising and communications) of the International Progressive MS Alliance, our collaboration with some of our member organisations to promote research into Progressive MS. During 2018 we contributed with many of our member organisations to the development of a new strategy for the next phase of the work of the Alliance. We have also continued to encourage all our member organisations to make renewed financial contributions to the work of the Alliance.

At the end of 2018, 16 MSIF members were participating in pooling funds for the Alliance. Additionally, there are now 16 Trust and Foundation Members and 6 members of the Industry Forum, which functions as an advisory body to the Alliance.

Fill strategic gaps in the pipeline of the MS Research workforce: Focus MSIF fellowships on emerging countries and widen alumni networking

During the whole or part of 2018 11 of MSIF's research-grant awardees were working on their research assignments. Additionally we awarded 2 new McDonald Fellowships and 5 Du Pré Grants. These grants enable promising young researchers from countries with low, lower middle or upper middle income (as defined by the World Bank) to undertake short working visits or extensive research programmes at global research centres of excellence. This helps to enhance the skills of researchers and clinicians from such countries and promotes more globally representative research collaborations.

Several of our research grants were supported by the Foundation for Support of MS Research (ARSEP, France), the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and MS Research Netherlands. For details on the award recipients in 2018 see: www.msif.org/news/2018/10/19/2018-mcdonald-fellowship-and-du-pre-grant-recipients-announced/ it is too early to report on the outcomes from the researchers we supported in 2018, we do know that over the period of 2012-2016 MSIF supported 65 young researchers from 26 countries, to do research in MS. Many have now returned and are contributing to MS research and care in their own countries. Over that same period, 50 papers (the target was 5) have been published in high quality journals by MSIF fellows/grantees. 12 Alumni (the target was 10) have been involved in establishing or volunteering for their national MS organisation during that period.

Developing an approach to address barriers to accessing treatments

To contribute to our aim of: Improved access to effective treatments and healthcare.

We set an objective for 2018 to:

- Develop an approach to address barriers to accessing treatments

The International Working Group on Access comprising staff from 7 member organisations (Australia, Canada, Guatemala, Ireland, Italy, the UK and the USA) which we established in 2017, made much progress in 2018. The year started off with a workshop in February where members of the working group, MSIF staff and outside experts decided on priority goals in the work of the global movement on access to treatment.

Firstly we agreed to focus on access to disease modifying treatments (DMTs).

Within this, we chose to aim to get several DMTs onto the World health Organisation's Essential

Medicines' list. The 'theory of change' underpinning this choice is that if we succeed in this, MS organisations around the world can use the listing as a strong argument in their advocacy to persuade national governments to ensure at least some of those drugs are available and reimbursed in their country. We worked closely with the global community of MS researchers and clinicians and their regional organisations, in proposing three such drugs. At the end of 2018 we made a submission to the WHO. The WHO will judge this submission in the first months of 2019.

We also chose to undertake a scoping exercise in relation to the regulatory systems for drugs in Latin American countries. This is particularly important in relation to the large number of follow-on products of biological drugs introduced in the region and the uncertainty amongst MS organisations and health care providers in the region about the efficacy and or safety of some of the drugs. This scoping exercise started in the second half of 2018.

To contribute to our aim of: A stronger, broader MSIF movement made up of effective MS organisations, engaged individuals and strategic international collaborations

We set objectives for 2018 to:

- Strengthen MS organisations in countries with challenging socio-economic conditions
- Enhance the effectiveness of member organisations and MSIF
- Ensure effective and inclusive international collaborations
- Strengthen communication and networking across the MSIF movement

Strengthen MS organisations in countries with challenging socio-economic conditions

Arab region

In Morocco the three MS organisations with which MSIF is working, came together to advocate for a reduction in import taxes on MS treatments. Local consultants are supporting the organisations to carry out their advocacy work which is the first joint project for the organisations.

Consultants working with Arfa MS Society in Saudi Arabia, as part of MSIF's country-focused capacity building work there, have held a series of workshops with the organisation's staff and board to discuss governance and operations ahead of supporting them with strategic planning. This has stemmed from the Society undergoing some personnel and structural changes.

During November the MS organisations in the region undertook a hugely successful region-wide awareness- raising campaign, entitled 'My dreams are your dreams'. This was the first time that the region campaigned together reaching out to young people without knowledge of MS. MSIF has worked with an agency in Kuwait to help deliver the campaign.

By being fully involved in all elements of the campaign, the national organisations in the region not only raised awareness, but also gained experience to run similar campaigns nationally and/or regionally in the future, and strengthened and promoted regional cooperation. As part of the campaign, MSIF awarded small grants to organisations in Iraq, Kurdistan region in Iraq, Lebanon, Saudi Arabia and Morocco to enable them to carry out or scale-up their campaign efforts.

Once again MSIF and the MENACTRIMS co-organised and co-funded a joint Regional Symposium during MENACTRIMS 2018 in November in Dubai, with an MSIF Regional Workshop following MENACTRIMS. A fixed term Capacity Building Support Officer was contracted to support this work.

Asia

In May, MSIF and the MS Society of India (MSSI) committed to working together to build the MSSI's profile and increase the impact and effectiveness of its country-wide work. In June, MSIF's Regional Capacity Building Manager led a workshop in Delhi, India with representatives from the eight MSSI Chapters which resulted in a decision to working together country-wide on advocacy.

During a second workshop the participants decided on the advocacy goal - getting state governments to enact the 2016 Rights of People with Disability Act and a project working group was also established.

Latin America

The MS Latin-American Network (LATEM), supported by MSIF has grown to include 17 countries in the region. Monthly digital meetings hosted by MSIF enabled the Network's working groups (focusing on social inclusion & stigma, legislation and good practice) to come together and share their ideas, problems and solutions.

The working groups prepared the 4th Regional Meeting, which took place in Asunción, Paraguay in November, following the Latin American Committee on Research and Treatment in MS (LACTRIMS) Congress.

MSIF has worked closely with the MS Association of Paraguay (APEMED), hosts of the Meeting, to support them with Meeting's logistics and content. By accompanying them through the planning process APEMED's volunteer leadership team gained their skills in collaborative working and fundraising as well as event management at a regional level.

MSIF has also provided ongoing guidance to a small planning committee tasked with coordinating the MS organisations-led session at the LACTRIMS 2018. This was a first for the organisations and a great opportunity to reach out to health professionals in the region and demonstrate the value of and contribution that MS organisations are making to improve the quality of life of people with and affected by MS.

Remote training for all MS organisations in the region took place in April. 21 representatives from 10 countries attended a webinar offering them guidance on working with healthcare industry.

MSIF initiated country-focused capacity-building work with MS Uruguay (EMUR). The work began with a workshop in Montevideo in May with local consultants providing EMUR's volunteers with mentoring and training in project management, HR and fundraising since then.

Country-focused work with the Brazilian MS Association (ABEM) has taken place with MSIF staff visiting São Paulo carrying out a 360 organizational diagnosis.

Enhance the effectiveness of member organisations and MSIF

A Board committee has worked through 2017 and 2018 to review MSIF's membership structure in order to ensure the structure supports collaboration and effectiveness and reflects the intentions and values of the new strategy. It has formulated proposals to open up MSIF's membership to more than one national MS organisation per country. After consultations with the membership and extensive discussions, the Board of Trustees approved this proposal. To put this into effect an amendment to MSIF's Articles is required which will be voted upon in 2019.

Evaluation forms from in person and online training events indicate we are providing opportunities for member organisations and their staff to try new things, learn from and support others and develop professional expertise. For example, here are some of the highlights from delegates who attended the 2018 World Conference which was organised in Rome in conjunction with the Italian MS Society:

"The experience of meeting and working together, to be strong!"

"To learn about services/events taking place in other countries"

"Young Persons workshop was inspiring. Building deeper relationships"

One of the lessons learned from this event was the need to pay even more attention to selecting those speakers who can address complicated issues in a way that everybody can understand and that briefing speakers on the need for accessible language is not enough.

Ensure effective and inclusive international collaborations

A major part of the strategy, this objective cuts across every aim, objective and action taken in 2018 and requires constant attention. In every area of our work we have established a number of working groups, committees and champions drawn from across the MS organisations ensuring our collaborative projects are truly international.

Kiss goodbye to MS

An increased PR spend on the 2018 campaign resulted in print and online media coverage to the value of £60,000 with the campaign being featured on Huffington Post Health, reaching 6 million readers. The 2018 campaign video was a huge success receiving over 385,000 views and featuring 8 new influencers. The number of member organisations participating in the campaign grew from 12 to 13.

Strengthen communication and networking across the MSIF movement

In 2018 we held two International Networking Meetings.
The first in Amsterdam in the Netherlands, facilitated by our Dutch member, Stichting MS Research, in April. The events included a visit to and meetings at the Nieuw Unicum Treatment and Expertise Centre for progressive forms of MS, Zandvoort where the presence of and interest shown by Queen Máxima of the Netherlands was very much appreciated.

The second occasion was the MS World Conference, held in Rome, Italy, facilitated by our Italian member, Associazione Italiana Sclerosi Multipla, which included a workshop for young people with MS from around the world.

Other topics covered during these meetings included:

- Action taken to make progress in research and treatment on Progressive MS and pregnancy
- Exchanges of best practice in fundraising
- Improved access to treatment and healthcare
- Reaching out to hard to reach groups

In between these two major in-person meetings we made extensive use of online and digital communications, collaboration tools and online platforms to facilitate communication and collaborative working between different functional groups within our member organisations.

To contribute to our aim of: Access to accurate and trustworthy information and resources to make informed decisions to live well with MS.

We set objectives for 2018 to:

- Repurpose and translate materials for adaption and use around the world
- Build networks of membership staff and volunteers in communications care and services.

Repurpose and translate materials for adaption and use around the world

The International Resource Group, which was formed in 2017 was expanded from 6 to 8 staff from our member organisations. Based on the outcome of a survey sent in 2017 to all members to assess the gaps in their access to information resources, it has worked to adapt and repurpose for national use around the world an animation on sex life and MS. This animation was based on one produced by the Italian MS Society (AISM). This is a great example of extending the use of the best national materials in the global MS movement for the benefit of many more MS organisations and through them many more people affected by MS around the world.

MS organisations have continued to recycle other materials. Multiple Sclerosis Spain (EME) has repurposed MSIF's Quality of Life Principles by producing a visually engaging guide that accompanies each principle with a set of tips. The Association of Patients with Neurodegenerative Conditions in Romania translated the Childhood MS Guide into Romanian, as well as producing a brochure on fatigue which recycled sections of MSIF's 2011 'MS in Focus' on the topic.

We continued to provide other high quality, trusted and independent information to the global MS community. We have worked with our member organisation, MS Research Australia, to produce research content for the MSIF website and the research newsletter.

Our e-newsletters are produced for the subscribers, but also as a resource for member organisations to reuse in their own country, to reach their own audiences.

Both our e-newsletters, MS Connections and MS Research News, are available in English, Spanish and Arabic, as are the majority of resources on our website.

Our social media pages are an important way to share our content and engage with our audiences, beyond our newsletters.

Build networks of membership staff and volunteers in communications, care and services.

The International Resource Group met in-person for the first time during the World Conference in Rome. This was an opportunity for members of the group to network and collaborate by sharing ideas and planning the project's development over the coming year. Fatigue was identified as the next resource to be created on the basis of the best materials existing in the global movement.

A number of staff and volunteers from member organisations also attended and spoke at a range of sessions on care, support, communications and awareness raising during the World Conference in Rome. These sessions were an opportunity for staff and volunteers to learn from, share best practice and network with delegates from across the world.

International Progressive MS Alliance

In June, staff from our member organisations participating in the International Progressive MS Alliance's communications and fundraising teams met to review its communications strategy, reviewing audiences, messages and channels. It was decided that the two work groups would merge, to ensure the Alliance has a strong, coherent and aligned approach in communications and fundraising.

To contribute to our aim of: Positive changes in policies and practices, attitudes and behaviours that are obstacles to living well with MS

In 2018 we said we would:

- Develop advocacy tools for national, local and individual action

Develop advocacy tools for national, local and individual action

The advocacy tools we developed and or worked on in 2018 related to World MS Day, the Quality of Life Principles and the next Atlas of MS.

World MS Day

World MS Day 2018 focused on research through the campaign #BringingUsCloser. This year saw record global participation, with over 900 online and in-person activities being held worldwide. 217 organisations participated in the day, which includes all MSIF members. World MS Day was marked in 104 countries around the world, with organisations in 14 of these countries either taking part for the first time, or for the first time in several years.

There was a significant rise in the reach of World MS Day on social media and in traditional media coverage.

Five member organisations - the Polish MS Association, the National Belgian MS Society, MS New

Zealand, Association for the Fight Against MS (Argentina) and the MS Society of India - were awarded small grants of £1000 each. The grants helped these five members transform the impact of their World MS Day activities.

The World MS Day working group (made up of staff and volunteers from member organisations) also worked on the theme, messaging and tools for World MS Day 2019, which will focus on visibility, through the campaign tagline of 'My Invisible MS'. The tools will include a My Invisible MS video which will feature people affected by MS from across the world speaking about their hidden symptoms. A design agency has supported us in developing an online tool creator. This will allow both MS organisations and people affected by MS to customise their own posters that can be shared through online channels.

Quality of Life Principles

Since the Quality of Life Principles were launched on World MS Day 2017, MSIF members have adapted, translated and incorporated the principles into their advocacy work in a number of ways, One example is how the MS Society of Canada used the principles to support national level advocacy to government and in a workshop with their programs and services team to see how they can be integrated in their daily work.MS Australia published an article promoting the Principles: 'The MSIF are on to something with their refreshed Quality of Life Principles for PwMS' MSA's Dr Sally Shaw, a social and psychological MS expert, wrote the article to:"encourage you to have a think about what quality of life means for you, and why the MSIF principles are worthy of your consideration.

Then I want to ask you to think about ways that you can improve your quality of life. Seriously. I believe that if you can identify the bits that are both important to you and within your control, you can then decide to make small, but extremely beneficial changes to increase your own experience of health and happiness in life. And surely that's got to be worth giving a crack."

Lastly, in Uruguay, EMUR used the principles at a Committee of associations of people with different disabilities, in order to submit to Uruguayan Legislators the MS community's needs and principles to improve Quality of Life. Other examples have been shared with us of how the Tunisian, German and American Members have used the principles so far, as well as translations into Italian, Dutch, and Portuguese in 2017 and in 2018, into Greek, Chinese and Polish. The most recent member to repurpose the Quality of Life Principles is Multiple Sclerosis Spain (EME), which has produced a highly engaging and visual guide in Spanish that accompanies each principle with a set of tips for living well with MS.



QUALITY OF LIFE WITH MS

What influences quality of life?

Many factors influence a person's quality of life, both inside and outside their direct control. These factors vary from person to person, from place to place and change over time. Multiple Sclerosis (MS) can impact these factors at any time.

How can quality of life be improved?

The seven principles below are based on the insights and experience of people affected by MS and agreed by the MSIF movement. There is no priority amongst the principles – it is for individuals and organisations to decide what is most important to them at any time. No country can claim to have achieved them all. They are our call to action for continuous improvement in every country.

The seven principles	Examples of factors they can influence
Empowerment, independence and a central role for people affected by MS in decisions that affect their lives	● ● ● ● ●
Access to comprehensive and effective treatments and care for the changing physical and mental health needs of life with MS	● ● ● ● ●
Support for the network of family, friends, loved ones and unpaid caregivers	● ● ● ● ●
Work, volunteering, education and leisure opportunities that are accessible and flexible	● ● ● ● ●
Accessible public and private spaces, technology and transport	● ● ● ● ●
Financial resources to meet the changing needs and costs of living with MS	● ● ● ● ●
Supportive attitudes, policies and practices that promote equality and challenge stigma and discrimination	● ● ● ● ●

Atlas of MS

We are still looking to publish the 3rd edition of the Atlas in 2020. We recruited a staff lead on the Atlas, to convene the working group and fine tune the plans for the use of as well as the production of the Atlas. Currently the plan features a survey of people with MS as well as the survey of MS organisations. We will explore options of working with an agency to implement aspects of the project.

Resourcing the Strategy

During 2018, our Finance Committee met in person once and three times by digi-meet. In the final meeting 3 year preliminary figures were presented up to 2021 alongside a fundraising plan and the 2019 budget was approved.

Performance of material fundraising against fundraising objectives

The targets for voluntary income at the start of 2018 were to raise £730,000 from pharmaceutical companies,
£148,238 from the Vanneau Trust and £960,500 from other sources (individuals, companies, member organisations, foundation and trusts, Kiss Goodbye to MS), altogether a total of £1,838,738.

We raised £566,278 from pharmaceutical companies, £148,500 from the Vanneau Trust, and £783,475 from other sources (individuals, companies, member organisations, foundations and trusts, Kiss Goodbye to MS), altogether a total of £1,498,253. In total we raised £340,485 less than the objectives set out in the budget, with some targets being adjusted to account for restricted funds brought forward from 2017.

Impact of fundraising expenditure on current and future income

The total cost of direct fundraising activities for 2018 was £139,745, approximately £43,000 was for income generated in 2018 and £96,000 was an investment in future income, in particular an investment in the Kiss Goodbye to MS fundraising programme, the Cykelnerven cycling fundraising programme and the so called 'DIY' fundraising programme. We also engaged a consultant based in the Middle East, to explore fundraising opportunities in the region, with an initial focus on the Gulf countries.

We expect that this investment will impact on the income growth of all these programmes in 2019, 2020 and 2021, as some of the initiatives, such as the one in the Middle East will take time to develop their full potential.

Investment performance against objectives set

The priorities for MSIF fundraising in 2018 were:

- Maintain current income levels
- Grow new income streams (Kiss Goodbye To MS, Cykelnerven, DIY fundraising, Middle East)

Overall we maintained 2017 income levels from existing channels in 2018. However, grants from the health care industry were £150,000 lower than expected due to one company discontinuing development of future MS related work and others restructuring their companies or facing delays in the development of their drugs.

MSIF's income from the 2018 Kiss goodbye to MS campaign is around £35,000, which is a £15,000 increase on 2017. The bulk of this growth has come from MSIF's own campaign income. Corporate and trust/foundation income hasn't materialised. Despite this, we will continue our efforts in this area as we are convinced progress must be possible.

In the second half of the year 'Facebook giving' began to develop, particularly relating to our World MS Day Facebook followers. Income from our 3 Facebook channels totalled £73,388. Our biggest channel was World MS Day was £56,531, followed by Kiss Goodbye to MS £13,523 and MSIF Facebook £3,333.

Managing external relationships

MSIF maintained and developed existing relationships with sponsors, including companies within the healthcare industry, individuals and foundations.

Protecting vulnerable people

MSIF employs two fundraising staff and, through its community fundraising it encourages members of the public to fundraise from their networks. The two main vehicles for this were Kiss Goodbye to MS and third party events. In 2018 there were three areas of MSIF's fundraising which have the potential to impact vulnerable people; Kiss Goodbye to MS, participation in third party events and web donations.

As we didn't conduct any email fundraising in 2018, making donations through the web was entirely voluntary and donors must have a credit card or PayPal account to complete a transaction. Both of these require a bank account, which have safeguarding practices of their own.

Kiss Goodbye to MS and marketing of the third party events both used social media, but both involve personal communication with MSIF. Through the donor support programme we interact directly with the individuals creating pages or signing up for events and staff are instructed to speak to the Director of Fundraising & Engagement if they have any concerns about an individual. We communicate with Facebook donors and audiences through the Facebook platform, both as a group to encourage fundraising and individually after they have donated. Facebook's own safeguarding policies therefore apply. In 2018 we refunded two donations made through Facebook due to errors and none due to safeguarding issues.

It is unlikely to be known when a donation is received that it is from a vulnerable person. However, MSIF is committed to protecting vulnerable people and if we are alerted to donation from a vulnerable person, or if a staff member has concerns, the *Acceptance and refusal of donations policy* (section 4.4) details the process that MSIF will adopt.

Regulations, standards and schemes

MSIF is subject to the UK Charity Commission and the Fundraising Regulator, plus the Information Commissioner's Office. MSIF has also published its Supporter promise on its website, which outlines the key principles by which we operate. We have a *Data protection policy*, a *Data security policy* and spent the latter part of 2017 updating our policies and practices to be in line with the new GDPR guidelines. All of the policies relating to public fundraising are available on the MSIF website.

Complaints

In 2018 MSIF received no complaints about its fundraising.

Financial review

Income was £340,485 less than budgeted. This was due to a reduction of £163,722 in contributions from the healthcare industry. Those reductions related to one company unexpectedly drastically reducing its activities in the field of MS and another one restructuring its operations. Furthermore, income contributions from member organisations was £204,978 less than budgeted. This risk was highlighted earlier in this report and one we anticipate continuing for years to come. Whilst members seem to be able to contribute to activities towards the aim of stopping MS, contributing to other aims such as improved access to health care, strengthening the MS movement, information provision or advocacy generally proves to be more difficult. We have planned discussions with our members about possible changes in our funding strategies and the way they contribute to the funding of global projects and MSIF's work.

However, a promising development in our income picture was the increase in income from individuals, which for the first time in more than 10 years exceeded targets by £45,000, with particularly strong results for income received via the Facebook channel. We expect that this trend will continue in 2019.

Expenditure was £141,975 lower than budgeted. This was due to some changes in staffing resulting in around £75,000 less expenditure, some £31,000 less expenditure on overheads, as well as some postponements of activities, notably the Atlas of MS.

The reserves policy, aims to reduce the unrestricted reserves over time to represent half a year core running costs (staff and overheads). Although, income was less than expected, the higher balances brought forward from 2017 (£197,523 higher than forecast) in combination with lower than budgeted expenditure, resulted in a higher than budgeted balance of unrestricted funds carried into 2019. As at 31 December 2018 we have unspent restricted funds of £83,718 and unrestricted funds of £1,094,210 and a designated fund of £80,000 for a potential office move.

Uncertainties remain about the ongoing developments around the United Kingdom's decision to leave the European Union. Given that much of MSIF's income comes from the USA, the European Union countries and generally from abroad, changes in the pound' exchange rates have so far not had a negative impact on MSIFs income.

Looking ahead, 2019 priorities

The long term Aims in the 2017-2021 Strategy	2019 objectives and actions towards these aims
Better scientific understanding leading to new ways to treat, prevent and stop MS.	• Advance systems for enabling data sharing, in particular focusing on Patient Reported Outcomes. In 2019 we will aim to widen this work through an important collaboration with a European organisation in the field of medical research and clinical application • Continue to engage our member organisations in a second phase strategy for the Progressive MS Alliance. • Continue to fill strategic gaps in the MS research workforces throughout the world.
Improved access to effective treatments and Health care.	• Continue our focus on getting MS drugs on the World health • Organisation's Essential Medicines List and undertake research into special challenges and possible solutions in Latin America.
Access to accurate and trustworthy information and resources to make informed decisions to live well with MS.	• Repurpose and translate materials for adaption and use around the world by facilitating the international resource group, made of dedicated staff from the membership, to produce resources in relation to fatigue and probably one other subject. • Deepen networks of membership staff and volunteers in communications, care and services, building on first meetings during the 2018 World conference in Rome.
Positive changes in policies and practices, attitudes and behaviours that are obstacles to living well with MS	• Develop advocacy tools for national, local and individual action, in particularly by coordinating World MS Day and continuing the work on an update of the Atlas of MS.
A stronger, broader MSIF movement made up of effective MS organisations, engaged individuals and strategic international collaborations	• Strengthen MS organisations in countries with challenging socio-economic conditions, with a continued focus the Arab region, Latin America and India. • Enhance the effectiveness of member organisations and MSIF, including through our International Networking meetings and a People with MS Forum in October 2019. • Ensure effective and inclusive international collaborations with a renewed structure and criteria for membership • Strengthen communication and networking across the MSIF movement.

In 2019 we will hold two board and global networking meetings, one in London and the second in another country in Europe. We will report progress against the above objectives and actions in the 2020 Report and Annual Accounts.

Audit information

So far as each of the directors at the time the trustees' report is approved is aware:

a) there is no relevant information of which the auditors are unaware; and

b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

Auditors

The auditors, Kingston Smith LLP, are deemed to be reappointed under section 487(2) of the Companies Act 2006.

Note of appreciation

We would like to offer our thanks for the generosity and support received from the people affected by MS, national MS society staff and volunteers, scientists and other professionals, together with our corporate and individual donors and sponsors who enable us to continue our activities.

Statement of trustees' responsibilities

The trustees (who are also directors of the Multiple Sclerosis International Federation for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of the financial statements may differ from legislation in other jurisdictions.

In preparing this report the Trustees have taken advantage of the small companies exemptions provided by section415A of the Companies Act 2006.

On behalf of Trustees

Weyman Johnson

Weyman Johnson, Chairman

Date: 12 April 2019

Independent auditor's report to the members of Multiple Sclerosis International Federation

Opinion

We have audited the financial statements of Multiple Sclerosis International Federation ('the company') for the year ended 31 December 2018 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard Applicable in the UK and Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2018 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or

- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a Strategic Report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Kingston Smith LLP

Date: 02/07/19

Luke Holt (Senior Statutory Auditor)

for and on behalf of Kingston Smith LLP, Statutory Auditor

Devonshire House
60 Goswell Road

London EC1M 7AD

Statement of Financial Activities for the year ended 31 December 2018

	Note	Unrestricted Funds	Restricted Funds	2018 Total Funds	2017 Total Funds
		£	£	£	£
Income and Expenditure					
Income from:					
Donations	2	75,973	1,085,337	1,161,310	1,569,701
Income from charitable activities					
Membership dues		321,778	-	321,778	317,334
Investment Income				-	
Bank Interest		3,053	-	3,053	1,583
Other					
Meeting Income		12,112	-	12,112	42,972
Total income		**412,916**	**1,085,337**	**1,498,253**	**1,931,590**
Expenditure on:					
Raising funds		136,324	30,785	167,109	89,449
Charitable activities					
Stopping MS		56,533	458,558	515,091	760,148
Improving access to treatment		55,114	102,182	157,296	73,792
Supporting informed decision making		16,347	180,725	197,072	155,653
Changing policies and practices		34,389	199,319	233,708	166,062
Constantly improving the MSIF movement		256,762	293,186	549,948	441,627
Unrestricted		-		-	26,273
Total expenditure	3 & 4	**555,469**	**1,264,755**	**1,820,224**	**1,713,004**
Net income/(expenditure)		(142,553)	(179,418)	(321,971)	218,586
Net movement in funds		(142,553)	(179,418)	(321,971)	218,586
Reconciliation of funds:					
Total funds brought forward		1,316,763	263,136	1,579,899	1,361,313
Total funds carried forward at 31 December 2018	10	**1,174,210**	**83,718**	**1,257,928**	**1,579,899**

All gains and losses arising in the period have been included in the Statement of Financial Activities and relate to continuing operation.

The accompanying notes on pages 30 to 47 are an integral part of these financial statements.

Balance Sheet as at 31 December 2018

	Note	2018 £	2017 £
Fixed Assets:			
Tangible Assets			
Equipment	6	7,038	759
		7,038	759
Current Assets:			
Debtors & prepaid expenses	7	260,934	227,204
Cash at bank & in hand	8	1,200,884	1,745,980
		1,461,818	1,973,184
Creditors: Amounts falling due within one year	9	(210,928)	(394,044)
Net current assets		1,250,890	1,579,140
Total Net Assets	10	1,257,928	1,579,899
The funds of the charity:			
Unrestricted funds		1,094,210	1,236,763
Designated fund	11	80,000	80,000
Restricted funds	12	83,718	263,136
		1,257,928	1,579,899

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The accompanying Notes on pages 30 to 47 are an integral part of these financial statements.

The accounts were approved by the Board and authorised for issue on 12 April 2019 and signed on its behalf by:

Victoria Annis
Treasurer

Cash Flow Statement for the year ended 31 December 2018

	2018 £	2017 £
Cash generated from / (used in) operating activities		
Net cash (used in)/provided by operating activities	(538,161)	437,311
Cash flows from investing activities		
Dividends, interest and rents from investments	3,053	1,583
Purchase of property, plant and equipment	(9,988)	(1,139)
Net cash provided by/(used in) investing activities	(6,935)	444
Change in cash and cash equivalents in the reporting period	(545,096)	437,755
Cash and cash equivalents at the beginning of the reporting period	1,745,980	1,308,225
Cash and cash equivalents at the end of the reporting perio	**1,200,884**	**1,745,980**

Reconciliation of net income/(expenditure) to net cash flow from operating activities

	2018 £	2017 £
Net income/(expenditure) for the reporting period (as per the statement of financial activities)	(321,971)	218,586
Adjustments for:		
Depreciation charges	3,709	3,893
Dividends, interest and rents from investments	(3,053)	(1,583)
(Increase)/decrease in debtors	(33,730)	104,241
Increase/(decrease) in creditors	(183,116)	112,174
Net cash provided by/(used in) operating activities	(538,161)	437,311

Prior Year Statement of Financial Activities

	Note	Unrestricted Funds £	Restricted Funds £	2017 Total Funds £
Income and Expenditure				
Income from:				
Donations	2	73,307	1,496,394	1,569,701
Income from charitable activities				
Membership dues		317,334	-	317,334
Investment Income				
Bank Interest		1,583	-	1,583
Other				
Meeting Income		42,972	-	42,972
Total income		435,196	1,496,394	1,931,590
Expenditure on:				
Raising funds				
Raising funds		59,449	30,000	89,449
Charitable activities				
Stopping MS		41,549	718,599	760,148
Improving access to treatment		20,585	53,207	73,792
Supporting informed decision making		-	155,653	155,653
Changing policies and practices		5,590	160,472	166,062
Constantly improving the MSIF movement		65,064	376,563	441,627
Unrestricted		26,273		26,273
Total expenditure	3 & 4	218,510	1,494,494	1,713,004
Net income/(expenditure)		216,686	1,900	218,586
Net movement in funds		216,686	1,900	218,586
Reconciliation of funds:				
Total funds brought forward		1,100,077	261,236	1,361,313
Total funds carried forward at 31 December 2016	10	1,316,763	263,136	1,579,899

All gains and losses arising in the period have been included in the Statement of Financial Activities and relate to continuing operation

Notes to the financial statements

1. Accounting policies

Basis of preparation

The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), published on 16 July 2014. The Charitable Company is a public benefit group for the purposes of FRS 102 and therefore the charity also prepared its financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP), the Companies Act 2006 and the Charities Act 2011.

Currency

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest pound.

Going concern

The financial statements have been prepared on a going concern basis.

Having carried out a detailed review of the Charity's resources and the current economic challenges facing both the Charity and its members the Trustees are satisfied that the Charity has sufficient cash flows to meet its liabilities as they fall due for at least one year from the date of approval of the financial statements. There are no material uncertainties.

Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

Financial instruments

Basic financial instruments are measured at amortised cost other than investments which are measured at fair value.

Debtors and creditors

Debtors and creditors receivable or payable within one year of the reporting date are carried at their transaction price and subsequently measured at amortised cost less any impairment.

Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the board is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are outlined below.

Useful economic lives

The annual depreciation charge for property, plant and equipment is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See note 6 for the carrying amount of the property, plant and equipment. The useful economic lives is currently three years and depreciation is provided on fixed assets in excess of £1,000.

Incoming resources

Income is recognised in the accounting period to which it relates. Membership dues, legacies and meeting income are accounted for when entitled, can be reasonably measured and the receipt is probable. Donated services are valued at the advised commercial rate.

Resources expended

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Wherever possible costs are directly attributed to these headings. The costs of generating funds are those costs of seeking potential funders and applying for funding. Support costs are those costs incurred in support of the charitable objectives. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Grant making policy

Grants are awarded by the Board to both individual and institutional recipients on the basis of their work. See Trustees' Report for detailed information.

Fund accounting

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors. The aim and use of each restricted fund is set out on the following pages.

Foreign currency

Transactions in foreign currency during the year are converted at the rate ruling at the date of transaction and any exchange differences arising are taken to the Statement of Financial Activities.

2 Donations

	Unrestricted Funds	Restricted Funds	Total 2018	Total 2017
	£	£	£	£
BiogenIdec	-	37,410	37,410	115,000
Celgene	-	51,609	51,609	7,406
Genzyme	-	167,612	167,612	165,742
Med Day	-	-	-	50,000
Merck Serono	-	152,607	152,607	125,000
Mr. Kamran Amour Dawoodzadeh and Family	-	-	-	37,781
MS Organisations - ECTRIMS	-	64,000	64,000	63,993
MS Organisations - MENACTRIMS	-	21,501	21,501	15,726
MS Societies	-	256,622	256,622	529,774
Novartis	-	42,040	42,040	-
Roche	-	115,000	115,000	130,000
Teva	-	-	-	110,000
Vanneau Trust	-	148,500	148,500	160,000
Wolfensohn Family Foundation*		7,166	7,166	7,406
Other	75,973	21,270	97,243	51,873
	75,973	1,085,337	1,161,310	1,569,701

Personal donations from Trustees during the period amounted to £1,914

* Income received from CAF

Prior Year Donations

	Unrestricted Funds	Restricted Funds	Total 2017	Total 2016
	£	£	£	£
BiogenIdec	-	115,000	115,000	120,000
Celgene	-	7,406	7,406	-
Genzyme	-	165,742	165,742	310,890
Med Day	-	50,000	50,000	-
Merck Serono	-	125,000	125,000	147,370
Mr. Kamran Amour Dawoodzadeh and Family	-	37,781	37,781	-
MSIF Foundation	-	-	-	11,819
MS Organisations - ECTRIMS	-	63,993	63,993	31,998
MS Organisations - MENACTRIMS	-	15,726	15,726	14,361
MS Societies	21,940	507,834	529,774	117,418
Roche	-	130,000	130,000	105,000
Teva	-	110,000	110,000	100,000
Vanneau Trust	-	160,000	160,000	343,500
Wolfensohn Family Foundation*		7,406	7,406	
Other	51,367	506	51,873	33,364
	73,307	1,496,394	1,569,701	1,335,720

Personal donations from Trustees during the period amounted to £4,757

* Income received from National MS Society, USA

3 Expenditure

	Direct Activities £	Grant Funding £	Support Costs £	Total 2018 £
Raising funds				
Raising funds	139,745	-	27,364	167,109
Charitable activities				
Stopping MS	26,057	306,621	182,413	515,091
Improving access to treatment	56,977	-	100,319	157,296
Supporting informed decision making	47,218	13,042	136,812	197,072
Changing policies and practices	35,881	33,661	164,166	233,708
Constantly improving the MSIF movement	132,909	116,059	300,980	549,948
	438,787	469,383	912,054	1,820,224

Grants payable comprises:

	Grants to Institutions £	Grants to Individual £	Total £
Stopping MS	305,121	1,500	306,621
Supporting informed decision making	7,542	5,500	13,042
Changing policies and practices	30,798	2,863	33,661
Constantly improving the MSIF movement	77,845	38,214	116,059
	421,306	48,077	469,383

Grants payable to institutions comprises:		Grants £
Progressive MS Alliance - National MS Society, USA		146,884
Associazione Italiana Sclerosi Multipla, Italy		39,628
Biogen - return of unspent restricted funds		32,700
Karolinska Institute Stockholm, Sweden		32,000
National Institute of Neuroscience Tokyo, Japan		32,000
University of Valencia, Spain		32,000
University of Melbourne, Australia		32,000
University of British Columbia, Canada		12,000
Genzyme - return of unspent restricted funds		9,491
MS Society, India		6,481
APEMED, Paraguay		8,293
University of Alberta, Canada		6,000
Bruno Brochet Centre Hospitalier Universitaire, France		6,000
Harvard Medical School, USA		5,800
AMMASEP, Morocco		5,000
AMMASEP, HANASEP, NORD.MA.SEP (Medact), Morocco		4,440
ALSEP, Lebanon		1,500
Saed MS Society, Saudi Arabia		1,514
Polskie Towarzystwo Stwardnienia Rozsianego, Poland		1,270
MS Society, New Zealand		1,000
Asociación de Lucha contra la Esclerosis Múltiple, Argentina		1,000
Ligue National Belge de la Sclerose en Plaques, Belgium		1,000
	Sub-total	418,001

continued

3 Expenditure continued

Sazgar MS Society, Iraq	891
Al Hayat MS Society Iraq	775
Unie Roska ceská MS společnost, Czech Republic	620
Al Razi MS Society, Iraq	582
Stichting MS Research, The Netherlands	437
	421,306

Grants payable outstanding comprises:

	Grants £
Progressive MS Alliance - National MS Society, USA	9,165
University of Valencia, Spain	32,000
University of Melbourne, Australia	32,000
National Institute of Neuroscience Tokyo, Japan	32,000
University of Alberta, Canada	6,000
University of British Columbia, Canada	6,000
Bruno Brochet Centre Hospitalier Universitaire, France	6,000
Harvard Medical School, USA	5,800
AMMASEP, HANASEP, NORD.MA.SEP (Medact), Morocco	2,200
	131,165

Prior Year Expenditure

	Direct Activities £	Grant Funding £	Support Costs £	Total 2017 £
Raising funds				
Raising funds	40,937	-	48,512	89,449
Charitable activities				
Stopping MS	37,403	536,779	185,966	760,148
Improving access to treatment	9,104	-	64,688	73,792
Supporting informed decision making	18,199	-	137,454	155,653
Changing policies and practices	35,630	9,146	121,286	166,062
Constantly improving the MSIF movement	132,489	58,478	250,660	441,627
Unrestricted	-	26,273	-	26,273
	273,762	630,676	808,566	1,713,004

Grants payable comprises:	Grants to Institutions £	Grants to Individuals £	Total 2017 £
Stopping MS	533,948	2,831	536,779
Changing policies and practices	9,146	-	9,146
Constantly improving the MSIF movement	5,732	52,746	58,478
Unrestricted	26,273	-	26,273
	575,099	55,577	630,676

Prior year expenditure continued

Grants payable to institutions comprises:

	Grants £
Progressive MS Alliance - National MS Society, USA	454,032
MRC Centre for Regenerative Medicine, Edinburgh	32,000
University of Valencia, Spain	32,000
University of Melbourne, Australia	32,000
NINDS, NIH, USA (grant not paid)	(32,000)
Genzyme (reallocation of funding)	26,273
Mayo Clinic, USA	5,000
University College London, UK	5,000
MS Society of Japan	4,832
University of Munster, Germany	4,000
International Pediatric Study Group	1,916
MS Society, Jordan	1,516
MS Organisation - Sudan	1,500
Associação Brasileira de Eslerose Múltipla, Brazil	1,263
Al Hayat MS Society Iraq	1,141
Greek MS Society	1,051
Maghrib MS Union	882
MS Society Berkane, Morocco	693
Union of Estonian Multiple Sclerosis Societies	500
MS-félag Íslands, Iceland	500
Unie Roska ceská MS společnost, Czech Republic	500
Esclerosis Múltiple Uruguay	500
	575,099

Grants payable outstanding comprises:

	Grants £
Progressive MS Alliance - National MS Society, USA	156,739
MRC Centre for Regenerative Medicine, Edinburgh	32,000
University of Valencia, Spain	32,000
University of Melbourne, Australia	32,000
Mayo Clinic, USA	5,000
University College London, UK	5,000
University of Munster, Germany	4,000
	266,739

4 Breakdown of expenditure

	Raising Funds	Stopping MS	Improving access to treatment	Supporting informed decision making	Changing policies & practices	Constantly improving the MSIF movement	Total 2018
	£	£	£	£	£	£	£
Direct Activities							
Conferences & Meetings	1,051	11,093	789	2,380	692	68,405	84,410
Travel & Accommodation	11,768	13,297	9,789	3,859	1,436	21,337	61,486
Professional Fees	125,347	1,667	46,399	39,566	33,541	43,126	289,646
Printing & Publications	1,579	-	-	1,413	212	41	3,245
Grants (note 3)	-	306,621	-	13,042	33,661	116,059	469,383
Sub Total	139,745	332,678	56,977	60,260	69,542	248,968	908,170
Support Costs							
Staff Costs (note 5)	23,106	154,038	84,720	115,529	138,630	254,160	770,183
Governance Costs	467	3,114	1,713	2,337	2,804	5,140	15,575
Education & Training	90	599	328	450	538	987	2,992
Rent, Rates & Insurance	2,505	16,704	9,184	12,529	15,031	27,555	83,508
Premises Maintenance	416	2,761	1,517	2,072	2,489	4,561	13,816
IT Support & Maintenance	554	3,691	2,030	2,769	3,321	6,091	18,456
Office Expenses	89	591	323	442	531	976	2,952
Financial Expenses	26	173	95	129	154	286	863
Depreciation (note 6)	111	742	409	555	668	1,224	3,709
Sub Total	27,364	182,413	100,319	136,812	164,166	300,980	912,054
Total Expenditure	167,109	515,091	157,296	197,072	233,708	549,948	1,820,224

Auditors' Fees during the period amounted to £4,840 + VAT. Auditors' Other Services during the period amounted to Nil. (2017 - Auditors' Fees £4,840 + VAT. Auditors' Other Services - Nil)

Support costs including governance costs are apportioned on the basis of staff time

The above expenditure includes unrestricted expenditure of £555,469 (2017: £218,510) and restricted expenditure of £1,264,755 (2017: £1,494,494)

4 Prior year breakdown of expenditure

	Raising Funds	Stopping MS	Improving access to treatment	Supporting informed decision making	Changing policies & practices	Constantly improving the MSIF movement	Unrestricted	Total 2017
	£	£	£	£	£	£	£	£
Direct Activities								
Conferences & Meetings	1,321	15,610	5,300	766	846	85,695	-	109,538
Travel & Accommodation	9,025	11,999	3,377	1,090	2,270	22,682	-	50,443
Professional Fees	30,591	9,794	427	14,089	31,976	24,062	-	110,939
Printing & Publications	-	-	-	2,254	538	50	-	2,842
Grants (note 3)	-	536,779	-	-	9,146	58,478	26,273	630,676
Sub Total	**40,937**	**574,182**	**9,104**	**18,199**	**44,776**	**190,967**	**26,273**	**904,438**
Support Costs								
Staff Costs (note 5)	38,999	149,494	51,999	110,497	97,498	201,495	-	649,982
Governance Costs	1,638	6,282	2,184	4,641	4,095	8,466	-	27,306
Education & Training	504	1,933	673	1,428	1,260	2,605	-	8,403
Rent, Rates & Insurance	5,158	19,770	6,878	14,612	12,895	26,652	-	85,964
Premises Maintenance	665	2,551	887	1,886	1,666	3,439	-	11,095
IT Support & Maintenance	1,100	4,215	1,467	3,117	2,750	5,683	-	18,332
Office Expenses	201	771	269	571	503	1,042	-	3,357
Financial Expenses	14	54	19	40	35	72	-	234
Depreciation (note 6)	233	896	312	662	584	1,206	-	3,893
Sub Total	**48,512**	**185,966**	**64,688**	**137,454**	**121,286**	**250,660**	**0**	**808,566**
Total Expenditure	**89,449**	**760,148**	**73,792**	**155,653**	**166,062**	**441,627**	**26,273**	**1,713,004**

Auditors' Fees during the period amounted to £4,840 + VAT. Auditors' Other Services during the period amounted to Nil. (2016 - Auditors' Fees £4,840 + VAT. Auditors' Other Services - Nil)

Support costs including governance costs are apportioned on the basis of staff time

The above expenditure includes unrestricted expenditure of £218,510 (2016: £310,169) and restricted expenditure of £1,494,494 (2016: £1,071,807)

Activity headings have changed in line with our new strategy.

5 Staff Costs

	2018	2017
	£	£
Salaries	654,158	545,659
Social Security	55,617	58,305
Pensions and Other Costs	60,408	46,018
	770,183	649,982

The average number of employees during the year was 15. The average number of part time employees was 3, with their full time equivalent being 2. (2017 The average number of employees during the year was 11. The average number of part time employees was 2, with their full time equivalent being 1).

One employee received total taxable emoluments of between £90,000 and £99,999 during the year (2017 one £90,000 - £99,999) and defined contributions of £5,616 to a pension scheme (2017 £5,616). One other employee received total taxable emoluments between £60,000-£60,999 and defined contributions of £3,614 to a pension scheme. (2017 - £Nil).

A defined contribution pension scheme is provided. The costs for the period were £32,470, of which £459 was outstanding at the balance sheet date. (2017 The costs for the period were £28,645 which were all paid at the balance sheet date).

Key Management Personnel

Key management personnel include the Trustees and senior management. The total employee benefits, including pension costs and employer's national insurance, of the charity's key management personnel were £214,796 (2017: £179,070).

No Trustee received any remuneration from the charity in the period. During the period six Trustees received travel expenses totalling £11,343 from the charity (2017 - seven trustees received £7,721).

6 Fixed Assets

	Equipment
	£
Cost brought forward at 1 January 2018	33,290
Additions	9,988
Disposals	(5,616)
Cost/depreciation carried forward at 31 December 2018	**37,662**
Depreciation brought forward at 1 January 2018	32,531
Depreciation for the year	3,709
Disposals	(5,616)
Cost/depreciation carried forward at 31 December 2018	**30,624**
Net Book Value at 31 December 2018	**7,038**
Net Book Value at 31 December 2017	759

7 Debtors and Prepaid Expenses

	2018	2017
	£	£
Other Debtors	217,766	179,393
Prepayments	35,224	36,477
VAT Reclaimable	7,944	11,334
	260,934	227,204

8 Cash at bank and in hand

	2018	2017
	£	£
Bank Accounts	1,200,717	1,745,568
Cash	167	412
	1,200,884	1,745,980

9 Creditors: Amounts falling due within one year

	2018	2017
	£	£
Other Creditors	70,848	123,274
Accruals	140,080	270,770
	210,928	394,044

Please refer to note 3 to see which grants are included in the Accruals and Other Creditors balances.

10 Analysis of Net Assets between Funds

	Unrestricted	Restricted	Total
	£	£	£
Fixed Assets	7,038	-	7,038
Current Assets	1,378,100	83,718	1,461,818
Current Liabilities	(210,928)	-	(210,928)
	1,174,210	83,718	1,257,928

Prior Year Analysis of Net Assets between Funds

	Unrestricted	Restricted	Total 2015
	£	£	£
Fixed Assets	759	-	759
Current Assets	1,710,048	263,136	1,973,184
Current Liabilities	(394,044)	-	(394,044)
	1,316,763	263,136	1,579,899

11 Designated fund movement

	Balance 01.01.18	Resources Incoming	Resources Outgoing	Transfers	Balance 31.12.18
Unrestricted	1,236,763	412,916	(555,469)	-	1,094,210
Designated fund:					
Provision for potential office move	80,000	-	-	-	80,000
	1,316,763	412,916	(555,469)	-	1,174,210

Expenditure is anticipated in mid-2019 when our current lease expires

Prior Year Designated fund movement

	Balance 01.01.17	Resources Incoming	Resources Outgoing	Transfers	Balance 31.12.17
Unrestricted	1,100,077	435,196	(218,510)	(80,000)	1,236,763
Designated fund:					
Provision for potential office move	-	-	-	80,000	80,000
	1,100,077	435,196	(218,510)	0	1,316,763

12 Outline summary of restricted fund movements

	Balance 01.01.18 £	Resources Incoming £	Resources Outgoing £	Balance 31.12.18 £
Research fellowships & grants	37,148	182,407	190,776	28,779
Strategy & research coordination	-	107,147	79,167	27,980
Progressive MS	-	178,615	178,615	-
Data sharing	-	5,000	5,000	-
Increasing resources	-	5,000	5,000	-
Improving access to treatment	6,369	95,813	102,182	-
Resource development	31,984	47,974	65,261	14,697
Digital communications	9,846	47,974	57,820	-
Skills networks	13,159	18,660	25,557	6,262
MSIF Communications	10,097	21,990	32,087	-
World MS Day	29,903	88,722	118,625	-
Atlas	19,069	20,654	39,723	-
Awards	-	7,166	7,166	-
Advocacy	33,805	-	33,805	-
Global capacity building	11,797	50,306	62,103	-
Regional Programmes - Arab Region	26,511	101,501	128,012	-
Regional Programmes - Asia	-	25,000	19,000	6,000
Regional Programmes - Latin America	33,448	50,623	84,071	-
Kiss Goodbye to MS	-	30,785	30,785	-
	263,136	1,085,337	1,264,755	83,718

Prior Year Outline summary of restricted fund movements

	Balance 01.01.17 £	Resources Incoming £	Resources Outgoing £	Balance 31.12.17 £
Research fellowships & grants	1,734	140,995	105,581	37,148
Strategy & research coordination	-	125,000	125,000	-
Progressive MS	24	487,994	488,018	-
Improving access to treatment	-	59,576	53,207	6,369
Resource development	-	82,243	50,259	31,984
Digital communications	-	61,828	51,982	9,846
Skills networks	-	37,415	24,256	13,159
MSIF Communications	25,065	14,188	29,156	10,097
World MS Day	13,173	101,404	84,674	29,903
Atlas	-	59,499	40,430	19,069
Awards	-	7,406	7,406	-
Quality of Life Principles	61,763	4	27,962	33,805
Global capacity building	-	120,000	108,203	11,797
Regional Programmes - Arab Region	65,149	103,723	142,361	26,511
Regional Programmes - Latin America	94,328	65,119	125,999	33,448
Kiss Goodbye to MS	-	30,000	30,000	-
	261,236	1,496,394	1,494,494	263,136

The purposes of the restricted funds are as follows:

Stopping MS

Research Fellowships & Grants: McDonald Fellowships are awarded to young researchers from emerging countries for research in MS. The two-year award includes a grant to cover travel and living costs, and an additional contribution of £2,000 per year to the host laboratory. The total award is a maximum of £30,000 per annum with up to three fellowships per year.
Du Pre Grants enable young researchers to undertake short visits to MS research centres of excellence. Each grant is £1,000 - £6,000 to cover travel costs or as a top-up to an existing grant. MSIF makes up to 5 grants per year. The Charcot Award is awarded for a lifetime achievement in outstanding research into the understanding or treatment of MS. The winner gives the Charcot Lecture at ECTRIMS. Their travel costs, and expenses are covered, up to a maximum of £5,000. A grant of £1,500 is awarded to the winner.

Strategy & research coordination: Facilitate, co-fund and cooperate and support common action by national MS organisations in relation to international research programmes/conferences. This involves the International Research Staff Network, International Medical and Scientific Board (IMSB) and liaison with the international MS research community.

Data Sharing: The programme of work encompasses our support for an international initiative to establish a global consensus around patient reported outcomes, and also our participation or collaboration in any internationally-relevant initiatives about sharing research/patient/clinical data relevant to MS.

Increasing resources: This programme of work aims to support encourage and support our member organisations to raise more funds for research. The most prominent part of this programme is the global Kiss Goodbye to MS campaign which focuses mostly on raising funds for research.

Progressive MS: Activities and support related to progressive MS as well as to the Alliance with sixteen of our member organisations to expedite the research into treatments for progressive MS.

Improving access to treatment

This programme aims to improve access for people with MS to all forms of healthcare, medical treatment and MS drugs around the world, that are effective, affordable, and of reliable quality.

Treatment information: Attend meetings and calls to contribute to the development of international guidelines on MS and provide funds to translate resulting materials.

Supporting informed decision making

Resource development: Repurpose and translate information materials for adaption and use around the world.

Digital communications: Any digital communication, including keeping MSIF's website up to date with free, trusted information about research, treatment and other aspects of MS, as well as MSIF's and our member's activities, for use by member organisations and other groups and individuals throughout the world. Prepare, send and translate (into Spanish and Arabic) MSIF's e-newsletters: Making Connections and Research News.

Skills Networks: Building the MSIF movement's capacity in communications, care and services through establishing and strengthening networks of relevant staff and volunteers from MS organisations and bringing them together to share skills and experience, proving training and development with the potential to develop international collaborative projects or replicate and adapt high quality projects in multiple countries.

MSIF communications: Funds for communications about the organisation itself, such as banners or materials and attendance at international conferences.

Changing policies and practices:

World MS Day: World MS Day (30 May) is an opportunity for people worldwide to join the global MS movement and participate in events and activities to raise awareness of MS as a global issue.

Atlas: The Atlas of MS presents data on the global, regional and national epidemiology of MS and the resources available for the treatment, management, rehabilitation and support of people with MS in every country with a significant prevalence of MS. Individuals, groups and organisations use it as a tool to illustrate the results of comparative analysis of epidemiology and resource data across geographical areas.

Awards (Nicholson & Wolfensohn): The James D Wolfensohn Award is given every two years to a person with MS in recognition of their valuable contribution to the fight against MS. The Evelyn Nicholson Award, given every two years, recognises people who are, or who have been, volunteer caregivers to people with MS and who have demonstrated outstanding commitment and devotion in the support of a loved one. Nominations for both these awards are submitted by MSIF member organisations and the winner is selected by MSIF's Person's with MS Committee. Every two years people with and affected by MS gather to give direct input into the work of the Global MSIF movement at the People with MS Forum facilitated by MSIF.

Advocacy: Includes the Quality of Life Principles is a framework that sets out what is required for people with MS to have the best possible quality of life.

Constantly Improving the MSIF movement

Global and other countries: building capacity, by supporting member organisations, amongst others through coaching, visits, exploring new partnerships and providing travel grants for attendance at meetings.

Regional Programmes - Arab Region: Build capacity, by initiating or supporting the development of MS organisations in Arabic speaking countries.

Regional Programmes - Latin America: Build capacity by supporting the development of MS organisations in Latin America.

Regional Programmes – Asia: Build capacity, by initiating or supporting the development of emerging MS support structures and groups and MS organisations in Asia, including through small grants for workshops, world MS Day activities and newsletters.

Kiss Goodbye to MS: an international campaign that enables people around the world to raise funds for vital research into MS and support people living with MS today.

13 Future Commitments

At 31 December 2018, MSIF had total minimum lease payments under operating leases as set out below:

	2018 £	2017 £
Equipment		
Less than one year	700	700
One to four years	1,575	2,275
Land and Buildings		
Less than one year	27,995	58,725
One - five years	380,093	27,995
	410,363	89,695

14 Related Party Disclosures

Name of Entity	Nature of Relationship	Membership Dues Received 2018 £	Membership Dues Received 2017 £
Ligue Nationale Belge de la Sclérose en Plaques, Belgium	Joint Trustee and Chairman	6,360	6,175
MS Society of Canada	Joint Trustee	32,683	31,741
Greek MS Society	Joint Trustee and Treasurer	-	348
MS Care, Egypt	Joint Trustee	12	11
Ligue Francaise contre la Sclerose En Plaques, France	Joint Trustee and Treasurer	6,544	6,544
MS Society India	Joint Trustee and Chairman	495	550
Stichting MS Research, Netherlands	Joint Trustee	3,503	3,500
Esclerosis Multipla Espana, Spain	Joint Trustee	352	341
National MS Society, USA	Joint Trustees and Chairman	110,004	110,004

Name of Entity	Membership Dues Accrued 2018 £	Membership Dues Accrued 2017 £
EMA, Argentina	351	-
Associação Brasileira de Eslerose Múltipla, Brazil	703	683
Union of Estonian Multiple Sclerosis Societies	19	23
MS Society of Greece	293	-
MS Society, Guatemala	12	-
MS Society India	-	550
Multiple Sclerosis Society of Malta	-	21
Polskie Towarzystowo Stwardnienia, Poland	-	892
UK MS Society	27,244	-

Name of Entity	Nature of Relationship	Grants Received 2018 £	Grants Received 2017 £
Scleroseforeningen, Denmark	Member	14,137	-
Neuroliitto, Finland	Joint member Progressive MS Alliance	-	52,438
Neuroliitto, Finland	Member	275	548
MS Forbundet, Norway	Joint member Progressive MS Alliance	23,015	47,687
MS Forbundet, Norway	Member		1,221
Stichting MS Research, Netherlands	Member	12,106	10,000
Stichting MS Research, Netherlands	Joint member Progressive MS Alliance	44,080	43,952
Ligue Française contre la Sclérose En Plaques, France	Joint member Progressive MS Alliance	8,985	105,455
Ligue Française contre la Sclérose En Plaques, France	Member	934	1,014
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques, France	Joint member Progressive MS Alliance	-	104,362
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques, France	Member	64,000	32,000
MS Ireland	Joint member Progressive MS Alliance	1,313	8,575
MS Ireland	Member	3,517	3797
MS New Zealand	Member		562
Esclerosis Multipla Espana, Spain	Joint member Progressive MS Alliance	48,017	87,244
Esclerosis Multipla Espana, Spain	Member	2,098	3,436
MS Society, UK	Member	28,522	1,611
National MS Society, USA	Member	5,623	33,278
Progressive MS Alliance - National MS Society, USA	Joint member	-	-

Name of Entity	Nature of Relationship	Grants Paid 2018 £	Grants Paid 2017 £
Progressive MS Alliance - National MS Society, USA	Joint member	146,884	454,032
ALCEM, Argentina	Member	1,000	-
Ligue National Belge de la Sclersoe en Plaques, Belgium	Member	1,001	-
Asociación de Lucha contra la Esclerosis Múltiple, Brazil	Member	-	1,263
Unie Roska ceská MS společnost, Czech Republic	Member	620	500
Union of Estonian Multiple Sclerosis Societies	Member	-	500
MS Society, Greece	Member	-	1,051
MS-félag Íslands, Iceland	Member	-	500
MS Society, India	Member	6,481	-
Associazione Italiana Sclerosi Multipla, Italy	Member	39,628	-
MS Society, Japan	Member	-	4,832
ALSEP, Lebanon	Member	1,500	-
Stichting MS Research, The	Member	437	-
Polskie Towarzystwo Stwardnienia Rozsianego, Poland	Member	1,270	-
MS Society, New Zealand	Member	1,000	-
Esclerosis Múltiple Uruguay	Member	-	500

Prior Year Related Party Disclosures

Name of Entity	Nature of Relationship	Membership Dues Received 2017 £	Membership Dues Received 2016 £
Ligue Nationale Belge de la Sclérose	Joint Trustee	6,175	6,144
MS Society of Canada	Joint Trustee	31,741	31,583
Sclerosforeningen, Denmark	Joint Trustee	-	-
Greek MS Society	Joint Trustee	348	348
MS Care, Egypt	Joint Trustee	11	9
Ligue Francaise contre la Sclerose En Plaques, France	Joint Trustee and Treasurer	6,544	6,625
MS Society of India	Joint Trustee and Chairman	550	495
Associazione Italiana Sclerosi Multipla of Italy	Joint Trustee and Chairman	-	31,749
Stichting MS Research, Netherlands	Joint Trustee	3,500	3,500
Esclerosis Multipla Espana, Spain	Joint Trustee	341	340
National MS Society, USA	Joint Trustee	110,004	110,004

Name of Entity	Membership Dues Accrued 2017 £	Membership Dues Accrued 2016
Associação Brasileira de Eslerose Múltipla, Brazil	683	-
Union of Estonian Multiple Sclerosis Societies	23	-
MS Society India	550	-
Multiple Sclerosis Society of Malta	21	-
Polskie Towarzystowo Stwardnienia, Poland	892	-

Name of Entity	Nature of Relationship	Grants Received 2017 £	Grants Received 2016 £
Ligue Nationale Belge de la Sclérose en Plaques, Belgium	Joint member Progressive MS Alliance	-	68,200
Ligue Nationale Belge de la Sclérose en Plaques, Belgium	Member	-	3,188
Neuroliitto, Finland	Joint member Progressive MS Alliance	52,438	-
Neuroliitto, Finland	Member	548	-
MS Forbundet, Norway	Joint member Progressive MS Alliance	47,687	-
MS Forbundet, Norway	Member	1,221	-
Stichting MS Research, Netherlands	Member	10,000	7,500
Stichting MS Research, Netherlands	Joint member Progressive MS Alliance	43,952	-
Ligue Française contre la Sclérose En Plaques, France	Joint member Progressive MS Alliance	105,455	-
Ligue Française contre la Sclérose En Plaques, France	Member	1,014	-
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques, France	Joint member Progressive MS Alliance	104,362	-
Fondation pour l'Aide à la Recherche sur la Sclérose En Plaques, France	Member	32,000	-
MS Ireland	Member	3,797	-
MS Ireland	Joint member Progressive MS Alliance	8,575	5,192

Prior Year Related Party Disclosures Continued

Name of Entity	Nature of Relationship	Grants Received 2017 £	Grants Received 2016 £
MS New Zealand	Member	562	-
Esclerosis Multipla Espana, Spain	Joint member Progressive MS Alliance	87,244	17,050
Esclerosis Multipla Espana, Spain	Member	3,436	5,548
MS Society, Uk	Member	1,611	-
National MS Society, USA	Member	33,278	-
Progressive MS Alliance - National MS Society, USA	Joint member	-	10,740

Name of Entity	Nature of Relationship	Grants Paid 2017 £	Grant Paid 2016 £
Progressive MS Alliance - National MS Society, USA	Joint member	454,032	90,679
Asociación de Lucha contra la Esclerosis Múltiple, Brazil	Member	1,263	-
Unie Roska ceská MS společnost, Czech Republic	Member	500	-
Sclerosforeningen, Denmark	Member	-	500
MS Care, Egypt	Member	-	464
Union of Estonian Multiple Sclerosis Societies	Member	500	-
MS Society, Greece	Member	1,051	-
MS-félag Íslands, Iceland	Member	500	-
MS Society, Japan	Member	4,832	-
Association Tunisienne des Malades de la Sclérose en Plaques, Tunisia	Member	-	4,787
Esclerosis Múltiple Uruguay	Member	500	-

15 Company Limited by Guarantee

Every full voting member undertakes to contribute such amount as may be required (not exceeding £10) to the company's assets if it should be wound up while it is a full voting member or within 1 year afterwards, 2018 32 members (2017 - 33 members)